Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy

Fig. 5

The ability of gold nanocages to deliver anti-VEGF siRNA to the lung cancer orthotopic murine model of BALB/c nude mice expressing NCI-H889 lung cancer cells. a Representative noninvasive imagings of NCI-H889 tumor-bearing nude mice in vivo (inhalation-mediated local delivery of 1 mL 800 µg mL− 1 Au-siRNA-PAA/Au-siRNA-PAA-AS1411 gold nanocages); (b) Quantitative biodistribution of self-assembled nanoparticles in lung tumors and organs based on the ROI (region of interest) analysis of the mean fluorescence intensity of each organ; c Quantification of Au accumulated in organs by ICP-MS. The data of Au-siRNA-PAA-AS1411 and Au-siRNA-PAA distribution in liver, spleen, lung (tumor), kidney and heart at 7 days after the inhalation-mediated local delivery of gold nanocages. The data in b and c are expressed as the mean ± SD (n = 6, ***P < 0.005) in each study group; d The bright field organ imaging of Au-siRNA-PAA-AS1411-treated mice; e The in vitro organ imaging of Au-siRNA-PAA-AS1411-treated mice; f Representative NCI-H889 lung-adenocarcinoma cells fluorescence and Au nanocage fluorescence analysis of ex vivo lungs from Au-siRNA-PAA-AS1411-treated mice

Back to article page